At a National Assembly audit, food and drug safety commissioner Oh Yu-kyung said the agency was reviewing an expansion of medical CBD for rare and essential diseases, while food and cosmetics uses needed more consideration. The remark followed 2026 bills to allow domestic CBD production and pressure on the imported supply of Epidiolex. No rule had changed by 28 October 2026.[1]
Listed for context. No score change is recorded for South Korea here.
References
- 약사공론 — 식약처장 “CBD 의료용 확대 검토…식품·화장품은 아직” (2026. 10. 27.)2026.10.27. 국회 보건복지위 종합국감, 오유경 처장 답변
Checked. The date and the event were compared with a source that was read.